22 Innovative Pharma Companies Secure New Funding Rounds and Advance Diverse Therapeutic Pipelines
Alebund
Developer of Kidney and Chronic Disease Treatment Products
Imunopharm
Developer of Gene and Cell Therapy Technologies
Insight Investment and Financing Database shows that 22 investment and financing events occurred in the global pharmaceuticals sector last week.(As of January 12)：
In terms of drug types, the fields that are highly favored by capital includeCAR-T Therapy, Gene Therapy, Macrocyclic Compounds, Peptides, Bioprinted Tissue Therapyetc.
In terms of regional distribution,Biotechs Securing Funding Are Mainly from the United States, accounting for 50%; in China, several Chinese companies have also completed new rounds of financing, includingAlebund, Blood霁 Bio,Yimiao Shenzhouetc.
Among the new forces in overseas financing, two companies have just introduced products from Chinese companies, respectively:Verdiva, fromXianweidaIntroducedIncludingIncluding orally administered Enoteglutide3 ProductsTheRights and Interests（Excluding Greater China and South Korea）；Timberlyne, fromConnoymabIntroducedCD38 Monoclonal Antibody CM313Overseas Rights.
China New Force Financing
Alebund Completes First Close of Series C Financing, Raising 550 Million Yuan
Alebund CompletesSeries C First Round 550 Million Yuan Financing。This roundJointly invested by a well-known industrial fund, Yangzhou Guojin Group, Xicheng Jinrui, and others, the financing fundsWill be used to advance itsRenal Disease PipelineThe development and commercialization, while accelerating the progress of multiple clinical projects.
Alebund was incubated in Shanghai, China in early 2018. It is mainly committed to the discovery, development, production, and commercialization of innovative drugs for kidney diseases and related chronic conditions. The company’s pipeline includes small molecule drugs and biologics, among which...AP301 is a novel iron-based oral phosphate binder., is conducting a pivotal Phase III study for the treatment of hyperphosphatemia in dialysis patients;AP306（EOS789）Is an oral pan-inhibitor of phosphate transporters, is currently conducting Phase II trials for the treatment of hyperphosphatemia in chronic kidney disease.
Alebund Financing History
Screenshot source: Insight database
Yimiao Shenzhou Completes Hundreds of Millions of Dollars in Series E Financing
Yimiao Shenzhou Announces CompletionHundreds of Millions of Dollars in Series E Financing, this roundByBeijing-Tianjin-Hebei Collaborative Development Industry Investment Fund Leads the Investment，Other investors include Taiping Healthcare Fund, Capital Development Group, and Si Ji Qing Investment, etc. The financing will be used to support itsFirst Original CAR-T Drug IM19The commercialization layout, and accelerate the research and development and clinical progress of new processes and products in fields including hematological tumors, solid tumors, and autoimmune diseases, etc.
Yimiao Shenzhou was founded in 2015 and focuses on applying innovative gene and cell drug technologies to the treatment of major diseases.Its first product, IM19, is an autologous CD19-targeted CAR-T cell product., generated by lentivirus transduction of T cells. This product was submitted for marketing approval in China in November 2024, with an indication for the treatment ofRelapsed or Refractory CD19-positive Non-Hodgkin Lymphoma, and is expected to be approved in Q1 2026.
Financing History of Yimiao Shenzhou
Blood霁 Biotech Receives Tens of Millions in Capital Investment
Xueji Bio announces securing tens of millions of yuan in capital investment from Zhongke Kangmei. This round of financing will be used to continue...To advance its multiple platelet-related pipelinesIND Application and Clinical Trial Initiation, further promotePreclinical Work on the First Pipeline of Platelet Drug Delivery, as well as the development of blood replacement and aesthetic medicine businesses.
Blood霁 Biotech was founded in June 2021 as a novel cell therapy company specializing in the in vitro regeneration of hematopoietic lineages, with a primary focus on the in vitro regeneration of platelets as its core development direction. In 2024, the company fully advanced...Multiple Blood Transfusion-Related PipelinesThe preclinical work and the development of new applications in the anti-aging field for platelet cell drugs, some pipelines are currently under dual submission in China and the US, and have obtained pediatric rare disease designation.
Blood霁 BioFinancing History
Screenshot source:Insight Database
Overseas New Financing
Verdiva Completes $411 Million Series A Financing
Verdiva Bio Announces Official Launch and Completion of $411 Million Series A Financing Co-led by Forbion and General Atlantic, with Other Investors Including RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and More.Verdiva focuses on developing innovative therapies for the treatment of obesity and other cardiometabolic diseases.
Verdiva hasAndXianweida Bio has achievedTotal amount up to 2.47 billion US dollarsCooperation，ObtainedXianweidaThe3 Product CombinationsGlobal Development and Commercialization License Outside Greater China and Korea. These three products include:Once-weekly oral GLP-1 receptor agonistOral Inogruotide（(Phase II clinical preparation stage)、Once a weekOralAmylin Receptor Agonist（Preclinical Stage）、Subcutaneous Injection of Amylin Receptor Agonist(Preclinical Stage)。
Timberlyne Secures $180 Million in Series A Financing Agreement
Timberlyne has reached a $180 million Series A financing agreement. This roundLed by Bain Capital Life Sciences, Venrock Healthcare Capital Partners, and Abingworth,Other investors include Boyu Capital, Lilly Asia Ventures, Braidwell, etc.
Timberlyne CompanyFocus on Developing New Therapies for Autoimmune Diseases. January 10, 2025,The company has reached an exclusive licensing agreement with Keymab., obtain globally(Excluding Greater China)Development, production and commercialization of the latterCD38 Monoclonal Antibody CM313The exclusive rights. According to the agreement, Keymab will receive a $30 million upfront payment and near-term payments, as well as obtain equity in Timberlyne, becoming the largest shareholder of the company.
Aviceda Completes $207.5 Million Series C Financing
Aviceda Therapeutics Announces Completion of $207.5 Million Series C Financing RoundJointly led by Omega Funds and TCGX,Other investors include Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, etc.This round of financing will be used forSupport AVD-104 ongoing Phase Ⅱb/Ⅲ and pivotalⅢ Phase clinical, for the treatment of geographic atrophy (GA)。
Aviceda focuses on developing the next generation of immune modulators, utilizing its proprietary HALOS nanotechnology platform to alleviate chronic, non-resolving inflammation.AVD-104 is an intravitreal glycan-coated nanoparticle with a dual mechanism of action, intended for the treatment of geographic atrophy secondary to age-related macular degeneration.In addition, Aviceda has established product lines in multiple therapeutic fields including ophthalmology, immunology, fibrosis, oncology, and neurology.
Tenvie Completes $200 Million Financing
Tenvie Therapeutics Announces Establishment and CompletionLed by ARCH Venture Partners, F-Prime Capital, and Mubadala CapitalThe $200 million financing. Tenvie is committed to transforming the treatment of neurological disorders.
Currently, Tenvie is developing a portfolio of small molecule products with high brain penetration and peripheral restriction, aiming to address three key drivers of disease: controllable inflammation.(Resolving Inflammation), rescuing metabolic dysfunction and restoring lysosomal function. Among them,The most advanced projects are NLRP3 inhibitors and allosteric SARM1 inhibitors., which is currently in the IND preparation stage. Other product lines include projects focused on neuroprotective pathways, including TRPML1 and TMEM175.
Aspect Biosystems Completes $115 Million Series B Financing
Aspect Biosystems Announces Completion of $115 Million Series B Financing RoundLed by Dimension,Novo Nordisk, Radical Ventures, InBC, and others followed up on the investment. This round of financing will enable Aspect to diversify its...Bioprinting Tissue TherapyPushed to the clinic, and expand its industry-leading tissue therapy platform.
Aspect focuses on developing bioprinted tissue therapies aimed at replacing, repairing, or supplementing biological functions in the body to transform the treatment of some refractory diseases.The company is advancing a series of bioprinted tissue therapies, covering multiple disease areas such as endocrine and metabolic disorders, and has entered into a collaboration with Novo Nordisk focused on diabetes and obesity.。
Orbis Completes €90 Million Series A Financing
Orbis Medicines Announces Completion of €90 Million Series A Financing RoundLed by New Enterprise Associates,Lilly, Cormorant, and the Danish Export and Investment Fund followed with investments. To date, the company's total financing has reached 116 million euros.
Orbis MedicinesCommitted to the R&D of oral macrolide drugsMacrocycles are a large and diverse class of compounds with highly desirable therapeutic properties, but developing them into oral drugs has been challenging. Orbis’s nGen platform is able to systematically deliver macrocycle candidates, called nCycles, which are optimized for oral bioavailability.This round of financing will be used to support Orbis in developing the next generation of oral macrolide drugs, nCycles.。
XyloCor Completes $67.5 Million Series B Financing
XyloCor Therapeutics Announces Completion of $67.5 Million Series B Financing RoundLed by Jeito Capital,EQT, Fountain Healthcare Partners, and Lumira Ventures also participated in the investment. This round of financing will be used to support two double-blind Phase II clinical trials of its leading candidate drug XC001, which has been proven to haveTreatment of Refractory AnginaThe potential.
XyloCor is committed toDevelopment of Novel Gene Therapies for Cardiovascular Diseases. Its main candidate product XC001 is in the clinical development stage,This product aims to promote the generation of new blood vessels in the heart, thereby bypassing diseased vessels and improving blood flow.. The second preclinical research product XC002 is in the discovery phase and is being developed forPatients with heart tissue damage caused by heart attacks。
In addition to the above cases, some other companies also made financing progress last week. Due to space limitations, they will not be introduced one by one here. For more financing information from last week, please click.「Read the Original Text」Go to Insight Database "New Drug Investment and Financing"ModelBlock View.
